The growth in the historic period can be attributed to improved diagnosis of pediatric growth hormone deficiency, expansion of pediatric endocrinology services, increased availability of recombinant growth hormone, rising awareness among caregivers, adoption of injection-based hormone therapy.
The growth in the forecast period can be attributed to increasing demand for patient-friendly growth hormone options, rising investments in long-acting biologics, expansion of home-administered hormone therapies, growing focus on treatment adherence, increasing approvals for pediatric hormone indications. Major trends in the forecast period include increasing adoption of long-acting growth hormone therapies, rising preference for weekly injection regimens, growing focus on pediatric treatment compliance, expansion of recombinant hormone innovations, enhanced emphasis on reduced injection burden.
Rising demand for hormone replacement therapy is expected to drive the growth of the Skytrofa market going forward. Hormone replacement therapy (HRT) is used to replace hormones such as estrogen and progesterone to relieve symptoms associated with menopause or other hormonal imbalances. The increasing demand for HRT is driven by an aging population and growing recognition of its benefits in managing menopause-related and hormone deficiency symptoms. Skytrofa is used to treat growth hormone deficiency by stimulating growth and development through subcutaneous injections. For instance, in October 2025, the National Health Service (NHS), a UK-based government body, reported that approximately 14.7 million HRT items were prescribed, representing an 11% increase compared with 2023/24. Therefore, rising demand for hormone replacement therapy is driving the growth of the Skytrofa market.
Increasing healthcare expenditure is expected to propel the growth of the Skytrofa market going forward. Healthcare expenditure refers to the total spending on medical services, treatments, and healthcare-related costs. Rising expenditure is driven by factors such as an aging population and the increasing prevalence of chronic diseases, both of which require more medical care and long-term treatments. Increased healthcare expenditure supports Skytrofa by funding research, improving treatment accessibility, and ensuring insurance coverage for patients with growth hormone deficiency. For instance, in November 2024, The Health Foundation, a UK-based independent charity, reported that planned day-to-day DHSC spending rose from $222.2 billion (£177.9 billion) in 2023/24 to $234.7 billion (£190.1 billion) in 2024/25, and is projected to reach $249.4 billion (£200.5 billion) in 2025/26, reflecting an average annual real-term growth of 3.3%. Therefore, increasing healthcare expenditure is driving the growth of the Skytrofa market.
Key companies in the Skytrofa market are focusing on developing innovative products, such as long-acting growth hormones, to improve patient convenience and treatment adherence. Long-acting growth hormones are formulations designed to be administered less frequently, typically weekly or monthly, while maintaining therapeutic effects, as opposed to daily injections. For instance, in September 2023, Ascendis Pharma A/S, a Denmark-based biotechnology company, launched SKYTROFA (lonapegsomatropin) in Germany, a once-weekly treatment for children and adolescents aged 3 to 18 years with growth hormone deficiency (GHD). This therapy simplifies the treatment regimen by offering a more convenient dosing schedule, using pegylation technology to extend the half-life of the medication, providing sustained effects over a week with a single injection. This advancement is aimed at improving patient adherence, reducing the burden of frequent injections, and enhancing the overall quality of care for young patients.
Major companies operating in the skytrofa market are Ascendis Pharma A/S.
North America was the largest region in the skytrofa market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the skytrofa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the skytrofa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are influencing the skytrofa market by increasing costs of imported biologic raw materials, recombinant protein manufacturing inputs, injection delivery devices, and cold-chain logistics systems. Pediatric healthcare providers in North America and Europe are most affected due to reliance on imported biologics, while Asia-Pacific faces cost pressures on formulation and distribution. These tariffs are raising treatment costs and affecting reimbursement dynamics. However, they are also supporting domestic biologics manufacturing, regional production capabilities, and long-term investments in pediatric hormone therapies.
The skytrofa market research report is one of a series of new reports that provides skytrofa market statistics, including skytrofa industry global market size, regional shares, competitors with a skytrofa market share, detailed skytrofa market segments, market trends and opportunities, and any further data you may need to thrive in the skytrofa industry. This skytrofa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Skytrofa is a long-acting recombinant human growth hormone (rhGH) used to treat pediatric growth hormone deficiency (GHD) through weekly subcutaneous injections. It promotes growth in children with GHD and offers a more convenient alternative to daily growth hormone therapies.
The primary indications for Skytrofa include growth hormone deficiency (GHD), idiopathic short stature (ISS), and Prader-Willi syndrome (PWS). Growth hormone deficiency occurs when the pituitary gland does not produce sufficient growth hormone, a crucial substance for growth, cell reproduction, and tissue regeneration. Skytrofa is available in liquid formulations and subcutaneous injections and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, clinics, ambulatory care centers, and home care settings.
The skytrofa market consists of sales of skytrofa injection devices, skytrofa diagnostic kits and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to increasing demand for patient-friendly growth hormone options, rising investments in long-acting biologics, expansion of home-administered hormone therapies, growing focus on treatment adherence, increasing approvals for pediatric hormone indications. Major trends in the forecast period include increasing adoption of long-acting growth hormone therapies, rising preference for weekly injection regimens, growing focus on pediatric treatment compliance, expansion of recombinant hormone innovations, enhanced emphasis on reduced injection burden.
Rising demand for hormone replacement therapy is expected to drive the growth of the Skytrofa market going forward. Hormone replacement therapy (HRT) is used to replace hormones such as estrogen and progesterone to relieve symptoms associated with menopause or other hormonal imbalances. The increasing demand for HRT is driven by an aging population and growing recognition of its benefits in managing menopause-related and hormone deficiency symptoms. Skytrofa is used to treat growth hormone deficiency by stimulating growth and development through subcutaneous injections. For instance, in October 2025, the National Health Service (NHS), a UK-based government body, reported that approximately 14.7 million HRT items were prescribed, representing an 11% increase compared with 2023/24. Therefore, rising demand for hormone replacement therapy is driving the growth of the Skytrofa market.
Increasing healthcare expenditure is expected to propel the growth of the Skytrofa market going forward. Healthcare expenditure refers to the total spending on medical services, treatments, and healthcare-related costs. Rising expenditure is driven by factors such as an aging population and the increasing prevalence of chronic diseases, both of which require more medical care and long-term treatments. Increased healthcare expenditure supports Skytrofa by funding research, improving treatment accessibility, and ensuring insurance coverage for patients with growth hormone deficiency. For instance, in November 2024, The Health Foundation, a UK-based independent charity, reported that planned day-to-day DHSC spending rose from $222.2 billion (£177.9 billion) in 2023/24 to $234.7 billion (£190.1 billion) in 2024/25, and is projected to reach $249.4 billion (£200.5 billion) in 2025/26, reflecting an average annual real-term growth of 3.3%. Therefore, increasing healthcare expenditure is driving the growth of the Skytrofa market.
Key companies in the Skytrofa market are focusing on developing innovative products, such as long-acting growth hormones, to improve patient convenience and treatment adherence. Long-acting growth hormones are formulations designed to be administered less frequently, typically weekly or monthly, while maintaining therapeutic effects, as opposed to daily injections. For instance, in September 2023, Ascendis Pharma A/S, a Denmark-based biotechnology company, launched SKYTROFA (lonapegsomatropin) in Germany, a once-weekly treatment for children and adolescents aged 3 to 18 years with growth hormone deficiency (GHD). This therapy simplifies the treatment regimen by offering a more convenient dosing schedule, using pegylation technology to extend the half-life of the medication, providing sustained effects over a week with a single injection. This advancement is aimed at improving patient adherence, reducing the burden of frequent injections, and enhancing the overall quality of care for young patients.
Major companies operating in the skytrofa market are Ascendis Pharma A/S.
North America was the largest region in the skytrofa market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the skytrofa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the skytrofa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are influencing the skytrofa market by increasing costs of imported biologic raw materials, recombinant protein manufacturing inputs, injection delivery devices, and cold-chain logistics systems. Pediatric healthcare providers in North America and Europe are most affected due to reliance on imported biologics, while Asia-Pacific faces cost pressures on formulation and distribution. These tariffs are raising treatment costs and affecting reimbursement dynamics. However, they are also supporting domestic biologics manufacturing, regional production capabilities, and long-term investments in pediatric hormone therapies.
The skytrofa market research report is one of a series of new reports that provides skytrofa market statistics, including skytrofa industry global market size, regional shares, competitors with a skytrofa market share, detailed skytrofa market segments, market trends and opportunities, and any further data you may need to thrive in the skytrofa industry. This skytrofa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Skytrofa is a long-acting recombinant human growth hormone (rhGH) used to treat pediatric growth hormone deficiency (GHD) through weekly subcutaneous injections. It promotes growth in children with GHD and offers a more convenient alternative to daily growth hormone therapies.
The primary indications for Skytrofa include growth hormone deficiency (GHD), idiopathic short stature (ISS), and Prader-Willi syndrome (PWS). Growth hormone deficiency occurs when the pituitary gland does not produce sufficient growth hormone, a crucial substance for growth, cell reproduction, and tissue regeneration. Skytrofa is available in liquid formulations and subcutaneous injections and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, clinics, ambulatory care centers, and home care settings.
The skytrofa market consists of sales of skytrofa injection devices, skytrofa diagnostic kits and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Skytrofa Market Characteristics
3. Skytrofa Market Supply Chain Analysis
4. Global Skytrofa Market Trends and Strategies
5. Skytrofa Market Analysis of End Use Industries
7. Global Skytrofa Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Skytrofa Total Addressable Market (TAM) Analysis for the Market
9. Skytrofa Market Segmentation
10. Skytrofa Market Regional and Country Analysis
11. Asia-Pacific Skytrofa Market
12. China Skytrofa Market
13. India Skytrofa Market
14. Japan Skytrofa Market
15. Australia Skytrofa Market
16. South Korea Skytrofa Market
17. Western Europe Skytrofa Market
18. UK Skytrofa Market
19. Germany Skytrofa Market
20. France Skytrofa Market
21. Eastern Europe Skytrofa Market
22. North America Skytrofa Market
23. USA Skytrofa Market
24. Canada Skytrofa Market
25. South America Skytrofa Market
26. Middle East Skytrofa Market
27. Africa Skytrofa Market
29. Skytrofa Market Competitive Landscape and Company Profiles
32. Skytrofa Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Skytrofa Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses skytrofa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for skytrofa? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The skytrofa market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Growth Hormone Deficiency (GHD); Turner Syndrome; Idiopathic Short Stature (ISS); Prader-Willi Syndrome (PWS)2) By Formulation: Liquid Formulation; Subcutaneous Injection
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Hospital; Clinics; Ambulatory Care; Home Care
Companies Mentioned: Ascendis Pharma A/S
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Skytrofa market report include:- Ascendis Pharma A/S
